There is a reason this exact question — retatrutide vs. MariTide — is circulating in WhatsApp channels used by metabolic researchers in Business Bay, procurement desks at Abu Dhabi biotech firms, and compound sourcing teams connected to Dubai Health City. Both peptides (or peptide-derived constructs) are generating outsized Phase 2 excitement. Both target the GLP-1 receptor axis. Both appear, from press releases and conference abstracts, to be the next generation of metabolic research tools. The surface-level similarities are real. But one layer beneath the surface, the compounds are so different in structure, synthetic accessibility, and procurement reality that treating them as interchangeable research options is a significant analytical error.
This article is written specifically for research procurement professionals, principal investigators, and compound sourcing contacts across the UAE who need a grounded, data-anchored comparison — not marketing language — to make sourcing decisions in Q3 2026. We cover mechanism, trial data, molecular class, storage requirements, and the practical question: what can you actually order today for your lab in Sharjah, JBR, or the Palm? Everything in this article is framed as research-context information only.
The answer to the practical procurement question is clear before we even reach the mechanism section: retatrutide is available; MariTide is not. But understanding why MariTide is unavailable — and what that means for your research design — is the more valuable knowledge this piece delivers.
Retatrutide (development code LY3437943, Eli Lilly) is a 39-amino-acid acylated synthetic peptide engineered to engage three receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This profile is abbreviated GLP-1/GIP/GCG in academic literature and is referred to as a triple agonist or triagonist to distinguish it from dual agonists like tirzepatide (GLP-1/GIP only) and mono-agonists like semaglutide (GLP-1 only).
The rationale for hitting all three receptors simultaneously is grounded in complementary metabolic signalling. GLP-1R agonism suppresses appetite via hypothalamic pathways and slows gastric emptying. GIPR agonism at pharmacological (supraphysiological) doses produces an additive anorectic effect — an initially counterintuitive finding that has since been replicated in multiple animal model systems and supported by the Phase 2 human data. Glucagon receptor agonism is where retatrutide genuinely differentiates: GCGR activation upregulates hepatic fatty acid beta-oxidation and increases basal energy expenditure in a way that neither GLP-1R nor GIPR agonism provides alone. This makes retatrutide the only currently researchable triple-agonist peptide for studies probing all three arms of the incretin-glucagon axis in one compound.
Crucially for procurement: retatrutide is a peptide. Its 39-amino-acid backbone, including the C18 fatty acid acylation that extends its half-life, can be assembled by solid-phase peptide synthesis (SPPS), purified to research-grade purity (≥98%) by reverse-phase HPLC, confirmed by mass spectrometry, and lyophilised into stable vials. This is the manufacturing pathway behind the 5mg and 10mg vials that REVIVE LAB UAE currently holds in stock.
MariTide is a bispecific antibody-peptide conjugate. The scaffold is an IgG2 monoclonal antibody engineered to bind and antagonise (block) the GIP receptor. Conjugated site-specifically to that antibody are two GLP-1 receptor agonist peptide sequences. The combined pharmacology is therefore GIPR antagonism plus GLP-1R agonism — mechanistically opposite to tirzepatide on the GIP axis (agonism vs. antagonism) while sharing the GLP-1 agonist component.
The antibody scaffold confers a biological half-life measured in weeks, enabling the monthly dosing interval that is MariTide's most clinically distinctive feature. Monthly subcutaneous injection for obesity treatment is a meaningful differentiator versus weekly regimens. For clinical medicine, that is relevant. For research compound procurement, the antibody scaffold creates an absolute barrier.
Antibody-drug conjugates (ADCs) require mammalian cell expression systems — typically CHO or HEK293 cell lines — to produce the antibody component. The resulting protein must then undergo affinity chromatography, endotoxin removal, site-specific conjugation to the GLP-1 agonist peptide sequences, and a multi-step analytical release package that includes bioassay, glycosylation profiling, and SEC-HPLC aggregate analysis. No peptide contract manufacturer operates this infrastructure. No UAE research supplier, domestic or international, can reproduce AMG-133 outside Amgen's own biologics manufacturing facilities. This is not a regulatory gap that will close imminently — it is a structural reality of what the molecule is.
The anchor publication for retatrutide's research profile is Jastreboff et al. 2023, published in the New England Journal of Medicine. This randomised, double-blind, placebo-controlled Phase 2 trial enrolled adults with a BMI of 30 or higher and examined retatrutide across multiple escalating dose cohorts over 24 weeks. The highest-dose cohort produced a mean body-weight reduction of approximately 17.5% over that 24-week period — a signal that generated significant academic discussion because it approached magnitudes previously observed only at the 52-week endpoints of tirzepatide Phase 3 data, in half the study duration.
Beyond body weight, the Phase 2 data reported dose-dependent reductions in waist circumference, hepatic fat fraction assessed by MRI-PDFF, fasting triglycerides, blood pressure, and fasting insulin. The GCGR agonist component appears to be driving the hepatic fat outcomes specifically — an observation that has made retatrutide particularly interesting to researchers working in non-alcoholic fatty liver disease (NAFLD) adjacent metabolic models, where the glucagon axis is mechanistically central.
The Eli Lilly TRIUMPH Phase 3 programme is the follow-on clinical development path. TRIUMPH is a multi-arm, multi-thousand-participant global programme examining retatrutide in obesity and type 2 diabetes populations over durations extending to 72 weeks. As of mid-2026, sequential TRIUMPH readouts are accumulating in the literature and conference calendar. The ongoing data stream is directly sustaining research interest in retatrutide as a reference compound for triple-agonism metabolic studies — and is shaping what UAE-based labs are building their own in-vitro and authorised model-study protocols around.
Amgen's Phase 2 MariTide data, presented publicly in 2024, reported approximately 20% body-weight reduction over 52 weeks in participants with obesity who did not have type 2 diabetes, on a monthly dosing schedule. That is a statistically and clinically meaningful signal — particularly the durability implied by the monthly interval and the magnitude at a full year. Amgen has since initiated a Phase 3 programme under the MARITIME trial name, signalling that the company regards the Phase 2 data as sufficient to support large-scale confirmatory trials.
The research community's interest in MariTide's mechanism is therefore legitimate. The question of whether blocking GIPR (as MariTide does) versus agonising it (as tirzepatide and retatrutide do) produces convergent or divergent metabolic outcomes is a genuinely open mechanistic question with implications for understanding incretin biology. However — and this point cannot be stated clearly enough for procurement purposes — the existence of compelling Phase 2 clinical data does not create a research-procurable compound. It creates a clinically promising biologic in Amgen's pipeline. Any supplier anywhere in the UAE, GCC, or internationally claiming to offer MariTide, AMG-133, or a "GIPR antagonist GLP-1 agonist conjugate" as a research peptide should be challenged to provide mass spectrometry data demonstrating molecular weight consistent with an IgG2 antibody-peptide conjugate of approximately 150,000+ Da. That data will not exist, because the molecule cannot be made by peptide synthesis.
| Parameter | Retatrutide (LY3437943) | MariTide (AMG-133) |
|---|---|---|
| Molecule class | Synthetic acylated peptide | Bispecific IgG2 antibody-peptide conjugate |
| Receptor mechanism | GLP-1R agonist / GIPR agonist / GCGR agonist (triple) | GIPR antagonist + GLP-1R agonist (bispecific) |
| GIP receptor action | Agonism (activation) | Antagonism (blockade) — mechanistic opposite |
| Approximate molecular weight | ~4,600 Da (peptide range) | ~150,000+ Da (antibody range) |
| Production route | Solid-phase peptide synthesis (SPPS) | Mammalian cell expression + site-specific conjugation |
| Key Phase 2 weight-loss signal | ~17.5% at 24 weeks (Jastreboff et al. 2023, NEJM) | ~20% at 52 weeks (Amgen-reported Phase 2 data, 2024) |
| Phase 3 programme | TRIUMPH (Eli Lilly, ongoing readouts 2024–2026) | MARITIME (Amgen, initiated 2025–2026) |
| Research-grade procurement (UAE) | In stock — REVIVE LAB UAE, 5mg & 10mg vials | Not available from any supplier globally |
| COA / analytical documentation | HPLC purity (≥98%) + MS confirmation, per batch | Not applicable |
| Storage (lyophilised) | −20°C sealed; +4°C once reconstituted | Not applicable |
| UAE same-day delivery | Yes — REVIVE LAB UAE Dubai same-day | Not applicable |
5mg and 10mg vials · COA included · same-day Dubai dispatch · discreet cold-chain packaging · cash on delivery
Buy Retatrutide UAE — Same-Day Dubai Dispatch from REVIVE LAB UAEThe Jastreboff et al. 2023 NEJM Phase 2 trial examined retatrutide across multiple escalating dose cohorts. The titration levels documented in the published protocol include 2 mg, 4 mg, and 8 mg weekly doses as the principal experimental arms, with the 8 mg cohort producing the most pronounced metabolic signal across weight, hepatic fat, and cardiometabolic markers. This dose-range structure — 2/4/8 mg as the published research titration framework — is the reference point academic and research teams use when designing experimental protocols or literature-contextualising their in-vitro and authorised in-vivo studies.
REVIVE LAB UAE supplies retatrutide in 5mg and 10mg vials. These are the research-format vial sizes. They allow a researcher working in Dubai Science Park, an Abu Dhabi university facility, or a private lab in Sharjah to prepare working solutions calibrated against the titration ranges documented in the published Phase 2 record. A 5mg vial provides the compound mass required for receptor-binding affinity studies, cellular cAMP assay protocols, and in-vitro competition assays at GLP-1R, GIPR, and GCGR simultaneously. A 10mg vial supports extended or multi-arm in-vitro studies and authorised model work without mid-project reorder delays.
Every vial from REVIVE LAB UAE ships with a Certificate of Analysis documenting HPLC purity at ≥98%, mass spectrometry confirmation of the expected molecular weight, and a batch number traceable to synthesis and QC records. This documentation chain is the difference between a research compound that can be cited with specificity in a methods section and an undocumented grey-market product. For labs submitting institutional review documentation or publishing in peer-reviewed journals, compound provenance and analytical backing are not optional.
Retatrutide, as a lyophilised peptide, requires storage at −20°C in sealed vials until point of use. Once reconstituted in your chosen research buffer — sterile water, bacteriostatic water, or an appropriate vehicle for your assay system — the working solution should be held at +4°C and used within the timeframe defined by your lab's standard operating procedures. Freeze-thaw cycling of reconstituted peptide solution is a degradation risk and should be avoided by aliquoting at the point of reconstitution.
This cold-chain requirement is operationally non-trivial in the UAE. From May through September, ambient temperatures in Dubai, Abu Dhabi, and across the Emirates routinely exceed 40°C. Standard courier packaging is not rated for peptide cold-chain at these temperatures. REVIVE LAB UAE's dispatch operation uses pharmaceutical-grade insulated containers with gel packs calibrated for Gulf summer conditions — not standard gel packs that equilibrate to ambient within 4 to 6 hours, but extended-duration packs validated for the transport intervals relevant to deliveries reaching JBR, Business Bay, Sharjah, and Abu Dhabi. If a research supplier you are evaluating cannot confirm cold-chain packaging standards for UAE summer conditions, the compound arriving at your lab may have experienced temperature excursions incompatible with peptide integrity — regardless of what the COA says at point of dispatch.
Delivery logistics from REVIVE LAB UAE: orders placed before 2 PM receive same-day dispatch to Dubai, with delivery confirmed the same afternoon or evening to addresses including JBR, Dubai Marina, Business Bay, Palm Jumeirah, DIFC, Jumeirah, and Deira. Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, and Fujairah receive next-day 24h delivery. All external packaging is discreet — no product names, no company branding visible externally — a standard that research institutions and private labs across the UAE have consistently requested.
The practical research conversation in the UAE in mid-2026 is not really "retatrutide versus MariTide." It is "which available, characterised, analytically documented GLP-1-axis peptide best supports the metabolic research programme we are building?" MariTide is not part of that conversation for procurement purposes — it has never been procurable externally and will not become so while it remains in Amgen's clinical pipeline as a proprietary biologic. The live choice is retatrutide versus other available compounds such as research-grade semaglutide analogs or tirzepatide-format dual agonists.
Retatrutide's distinctive contribution to that comparison is the glucagon receptor arm. It is the only triple-agonist peptide available from a UAE research supplier. For investigators specifically studying hepatic lipid metabolism, thermogenic energy expenditure models, or the independent contribution of GCGR versus GLP-1R to body composition outcomes — retatrutide is the only available compound that enables those research questions to be asked in vitro or in authorised model systems without conflation between receptor pathways.
The accumulating TRIUMPH Phase 3 readouts from Eli Lilly are also creating a live and growing literature base. Labs at research institutions across Abu Dhabi's Saadiyat Island corridor, in the Dubai International Academic City cluster, and in university research departments in Sharjah that have already begun retatrutide-based in-vitro work are positioning themselves to contribute to and draw from that literature as it publishes. In competitive academic research environments, compound selection timing has priority implications. Waiting for a MariTide research analog that will not exist is not a strategy — it is a delay.
REVIVE LAB UAE has structured payment options to reflect how research procurement actually works across the Emirates. Cash on delivery (COD) is available for Dubai orders — your vials arrive, you verify the packaging and COA, then pay. No advance transfer required. Bank transfer and card payment are standard for Abu Dhabi, Sharjah, and other Emirate deliveries. Since June 2026, Binance Pay via USDT TRC20 is live as a second checkout pathway. A 5% pre-pay discount applies automatically for USDT transactions. Confirmation is handled via WhatsApp txid verification before dispatch — a flow that has been adopted by a growing number of institutional procurement accounts managing international compound sourcing through crypto treasury positions.
Yes. REVIVE LAB UAE stocks retatrutide in 5mg and 10mg vials for licensed research use. Orders placed before 2 PM receive same-day dispatch to Dubai, covering JBR, Marina, Business Bay, Palm Jumeirah, DIFC, and all other districts. 24h delivery covers Abu Dhabi, Sharjah, Ajman, and the wider UAE. Cash on delivery is available for Dubai. Binance Pay (USDT TRC20) available with a 5% pre-pay discount. Every shipment includes a COA with HPLC purity (≥98%) and mass spectrometry documentation.
Retatrutide is a synthetic acylated peptide and GLP-1/GIP/glucagon triple receptor agonist — procurable as a research compound from REVIVE LAB UAE with same-day Dubai delivery. MariTide (AMG-133) is Amgen's investigational bispecific IgG2 antibody-peptide conjugate: it antagonises (blocks) the GIP receptor while agonising the GLP-1 receptor — a different mechanism to retatrutide on the GIP side. More importantly for procurement, MariTide's antibody-drug conjugate structure cannot be reproduced by peptide synthesis and is not available from any research supplier in the UAE, GCC, or globally in 2026. UAE labs studying triple GLP-1-axis agonism work with retatrutide.
Yes. Same-day dispatch is standard for orders placed before 2 PM, with delivery across Dubai including JBR, Marina, Business Bay, Palm Jumeirah, DIFC, and Jumeirah. Abu Dhabi, Sharjah, Ajman, and Ras Al Khaimah receive next-day 24h delivery. All shipments use discreet outer packaging with no visible branding or product names and pharmaceutical-grade cold-chain insulation validated for UAE summer ambient temperatures. Retatrutide cash on delivery is available for all Dubai-area orders.
5mg · 10mg · COA included · discreet packaging · same-day Dubai · 24h UAE-wide · cash on delivery
Buy Retatrutide UAE — Order Now from REVIVE LAB UAE